BAJAJ BROKING
Dr. Reddy’s Laboratories delivered a strong Q2 FY24-25, showcasing substantial revenue growth with consolidated revenue reaching ₹80,162 million. However, profit after tax saw a slight decline. Explore detailed insights and segment breakdown.
Dr. Reddy’s Laboratories reported consolidated revenue of ₹80,162 million for Q2 FY24-25, a year-over-year increase of 17% and a quarter-over-quarter growth of 4%. Despite higher costs, the gross profit margin remained strong, supporting Dr. Reddy's growth across its generics and emerging markets segments.
The net profit after tax reached ₹13,415 million, a 9% decline YoY, mainly due to one-time expenses, including acquisition-related costs and tax adjustments. This stable financial performance, combined with strategic investments in research and partnerships, underscores Dr. Reddy’s ongoing commitment to operational efficiency and expansion into emerging markets.
Dr. Reddy’s Q2 results exceeded industry expectations, with a substantial increase in revenue from its generics segment, especially in North America and emerging markets. This growth aligns with the sector’s robust demand for generic drugs, while slight declines in profit were anticipated due to higher SG&A and R&D investments.
G V Prasad, Co-Chairman & MD of Dr. Reddy’s, noted, "We delivered another good quarter and maintained the growth momentum across businesses. We made progress on our future growth drivers, operationalized our venture with Nestle and completed the acquisition of Nicotinell® and related brands. We will continue to drive efficiency, strengthen our core businesses, and positively impact patient lives through science and innovation."
Metric | Q2 FY24-25 | Q1 FY24-25 | Q2 FY23-24 |
Revenue (₹ million) | 80,162 | 76,727 | 68,802 |
Gross Profit (₹ million) | 47,769 | 46,344 | 40,368 |
EBITDA (₹ million) | 22,803 | 21,599 | 21,813 |
PAT (₹ million) | 13,415 | 13,920 | 14,800 |
EPS (₹) | 15.07 | 16.72 | 17.80 |
Selling & Administrative Expenses | 23,007 | 22,691 | 18,795 |
R&D Expenses (₹ million) | 7,271 | 6,193 | 5,447 |
Check out Dr Reddy's Lab's past performances in previous quarters and financial years.
Dr. Reddy’s Q2 results for FY24-25 demonstrate a solid performance with significant revenue growth across core segments. Despite challenges from rising costs and tax adjustments, the company has maintained a stable profit margin, underscoring its resilience and strategic focus. With new acquisitions, partnerships, and a strong presence in emerging markets, Dr. Reddy’s is well-positioned for sustained growth in the coming quarters.
Disclaimer: Investments in the securities market are subject to market risk, read all related documents carefully before investing.
This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.
For All Disclaimers Click Here: https://bit.ly/3Tcsfuc
Share this article:
Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading